Clinical Trials

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

Have you been diagnosed with LAM? This study is trying to understand the genes and proteins that are responsible for causing lung damage in patients with LAM. To participate in this study, you must be between 16 and 99 years old and diagnosed with LAM. This study is located in Bethesda, Maryland.

Are you an adult female who has been diagnosed with LAM? This study is examining which delivery method of albuterol—inhaled or nebulizer—is better at improving lung function in adult women who have LAM. This study is located in Bethesda, Maryland.

Do you have LAM and would be willing to help research? This study aims to identify the right dose of sirolimus to treat people who have LAM. To participate in this study, you must be female, between 18 and 90 years old, and diagnosed with LAM. This study is located in Bethesda, Maryland.

Are you an adult woman who would like to help develop methods to prevent the worsening of LAM? This study aims to discover whether earlier and longer treatment with a lower dose of sirolimus can help prevent LAM from getting worse over time. To participate in this study, you must be female, be at least 18 years old, and have been diagnosed with LAM. This study is located in Atlanta, Georgia; Boston, Massachusetts; Chicago, Illinois; Cincinnati, Ohio; Denver, Colorado; Nashville, Tennessee; Palo Alto, California; Philadelphia, Pennsylvania; and Seattle, Washington.

A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE).

Are you an adult with sickle cell disease or would like to help research? Some people who have sickle cell disease are at greater risk for developing abnormal blood clots (venous thromboembolism). This could be a blood clot in the leg (called deep vein thrombosis) or a clot that can break off and travel to the lung (called a pulmonary embolism). This study will look at the blood of people who have sickle cell disease and venous thromboembolism, as well as healthy volunteers, to help researchers develop better treatments to prevent blood clots. Participants in this study must be between 18 and 80 years old and be either a healthy volunteer or have sickle cell disease or trait. This study is located in Bethesda, Maryland.

Are you an adult willing to give blood samples? This study investigates ways to prevent blood clotting in people with sickle cell disease. In this population, blood clotting is the most common cause of vascular death after heart attack and stroke. Scientists are studying the blood of people with sickle cell disease and comparing it with the blood of people without sickle cell disease over 2 years. To participate in this study, you must be between the ages of 18 and 80 years old and willing to participate for up to 2 years. This study takes place in Bethesda, Maryland.

This study is testing whether a new imaging technique can help healthcare providers diagnose venous thromboembolism. To participate in this study, you must be at least 18 years old and diagnosed with venous thromboembolism. This study takes place in Boston, Massachusetts.